94 results on '"Rowe, Jacob M"'
Search Results
2. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
3. Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
4. Consolidation in AML: Abundant opinion and much unknown
5. Changing trends in the therapy of acute myeloid leukemia
6. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial
7. ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia
8. Poster: ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia
9. Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia
10. Perspectives on current survival and new developments in AML
11. Risk of Cancer in Pediatric-Onset Inflammatory Bowel Diseases: A Nation-Wide Study from the Epi-Iirn
12. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
13. Will new agents impact survival in AML?
14. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy
15. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis
16. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
17. The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
18. Progress and predictions: AML in 2018
19. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome
20. Apograft, a Novel Stem Cell Selection Technology, Prevents Graft vs. Host Disease (GvHD) While Preserving Graft vs Leukemia (GvL) Effects
21. AML in 2017: Advances in clinical practice
22. Which patients should I transplant with acute lymphoblastic leukemia?
23. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
24. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
25. AML in 2016: Where we are now?
26. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience
27. Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy
28. Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria
29. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia
30. Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
31. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
32. Characterization of new cryptic rearrangements of the erythropoietin receptor in Ph-like acute lymphoblastic leukemia
33. Reasons for optimism in the therapy of acute leukemia
34. Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease Is Safe and Effective: 1 Year Follow-up and Mechanism of Action
35. Transplantation in Acute Myeloid Leukemia
36. The increasing genomic complexity of acute myeloid leukemia
37. Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
38. Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission
39. Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
40. Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis
41. Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft-versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation: A Phase I/IIa Clinical Trial
42. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial
43. Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia
44. Important milestones in acute leukemia in 2013
45. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death
46. All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129
47. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research
48. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management
49. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
50. The impact of mutational profiling on AML prognosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.